Evolent Health issued outlook for full year 2018 and the first quarter.
For full year 2018, the company expects adjusted revenue of approximately $565.0 million to $585.0 million, and adjusted EBITDA of about $18.0 million to $23.0 million. Adjusted services revenue is expected to be between about $495.0 million and $510.0 million, true health premium revenue is estimated to be about $90.0 million to $95.0 million, and intercompany eliminations are expected to be nearly $20.0 million.
For the first quarter, the company expects adjusted revenue of about $139.0 million to $143.0 million, and adjusted EBITDA of approximately $3.0 million to $5.0 million. Adjusted services revenue is expected to be approximately $122.0 million to $124.0 million, true health premium revenue is expected to be approximately $22.0 million to $24.0 million, and intercompany eliminations are estimated to be roughly $5.0 million for the quarter.
For the fourth quarter of 2017, Evolent Health reported a net loss attributable to the company of $13.2 million, or 18 cents per share, compared to a net loss of $17.4 million, or 33 cents per share, in the year-ago period.
The S&P Capital IQ consensus GAAP EPS estimate for the fourth quarter of 2017 was a loss of 17 cents.
For full year 2017, the company posted a net loss attributable to the company of $60.7 million, or 94 cents per share, compared to a net loss of $159.7 million, or $3.55 per share, in 2016.
The S&P Capital IQ consensus GAAP EPS estimate for 2017 was a loss of 92 cents.
